全文获取类型
收费全文 | 13443篇 |
免费 | 1401篇 |
国内免费 | 112篇 |
专业分类
耳鼻咽喉 | 149篇 |
儿科学 | 361篇 |
妇产科学 | 310篇 |
基础医学 | 1788篇 |
口腔科学 | 428篇 |
临床医学 | 1998篇 |
内科学 | 2289篇 |
皮肤病学 | 247篇 |
神经病学 | 1098篇 |
特种医学 | 698篇 |
外国民族医学 | 3篇 |
外科学 | 1869篇 |
综合类 | 338篇 |
一般理论 | 9篇 |
预防医学 | 1159篇 |
眼科学 | 215篇 |
药学 | 1100篇 |
中国医学 | 10篇 |
肿瘤学 | 887篇 |
出版年
2021年 | 130篇 |
2019年 | 156篇 |
2018年 | 187篇 |
2017年 | 162篇 |
2016年 | 165篇 |
2015年 | 192篇 |
2014年 | 248篇 |
2013年 | 397篇 |
2012年 | 505篇 |
2011年 | 536篇 |
2010年 | 350篇 |
2009年 | 362篇 |
2008年 | 510篇 |
2007年 | 620篇 |
2006年 | 562篇 |
2005年 | 524篇 |
2004年 | 504篇 |
2003年 | 475篇 |
2002年 | 528篇 |
2001年 | 493篇 |
2000年 | 508篇 |
1999年 | 440篇 |
1998年 | 233篇 |
1997年 | 205篇 |
1996年 | 239篇 |
1995年 | 229篇 |
1994年 | 231篇 |
1993年 | 194篇 |
1992年 | 313篇 |
1991年 | 325篇 |
1990年 | 312篇 |
1989年 | 285篇 |
1988年 | 295篇 |
1987年 | 270篇 |
1986年 | 285篇 |
1985年 | 284篇 |
1984年 | 201篇 |
1983年 | 173篇 |
1982年 | 109篇 |
1981年 | 131篇 |
1980年 | 110篇 |
1979年 | 181篇 |
1978年 | 121篇 |
1977年 | 123篇 |
1976年 | 117篇 |
1974年 | 109篇 |
1973年 | 108篇 |
1972年 | 109篇 |
1971年 | 99篇 |
1968年 | 112篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Hui Yu Zhengming Chen Karla V. Ballman Mark A. Watson Ramaswamy Govindan Irena Lanc David G. Beer Raphael Bueno Lucian R. Chirieac Michael Herman Chui Guoan Chen Wilbur A. Franklin David R. Gandara Carlo Genova Kristine A. Brovsky Mary-Beth M. Joshi Daniel T. Merrick William G. Richards Fred R. Hirsch 《Journal of thoracic oncology》2019,14(1):25-36
Objectives
Anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in stage IB to IIIA NSCLC. In addition, several clinical trials using anti–PD-1/PD-L1 immunotherapy as an adjuvant or neoadjuvant treatment in patients with resectable stage NSCLC are ongoing. However, few analyses of anti–PD-1/PD-L1 immunotherapy–related biomarkers in early-stage squamous cell lung carcinoma (SqCLC) have been reported. In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC, providing data for identifying the potential role for patients with anti–PD-1/PD-L1 treatment in early-stage SqCLC.Methods
A total of 255 specimens from patients with early-stage SqCLC were identified within participating centers of the Strategic Partnering to Evaluate Cancer Signatures program. PD-L1 protein expression by immunohistochemistry was evaluated by using the Dako PD-L1 22C3 pharmDx kit on the Dako Link 48 auto-stainer (Dako, Carpinteria, CA). Tumor mutation burden (TMB) was calculated on the basis of data from targeted genome sequencing. The T-effector and interferon gamma (IFN-γ) gene signature was determined from Affymetrix gene chip data (Affymetrix, Santa Clara, CA) from frozen specimens.Results
The prevalence of PD-L1 expression was 9.8% at a tumor proportion score cutoff of at least 50%. PD-L1 mRNA and programmed cell death 1 ligand 2 mRNA positively correlated with PD-L1 protein expression on tumor cells (TCs) and tumor-infiltrating immune cells. PD-L1 protein expression on tumor-infiltrating immune cells was correlated with the T-effector and IFN-γ gene signature (p < 0.001), but not with TMB. For TCs, all of these biomarkers were independent of each other and neither PD-L1 protein expression, TMB, or T-effector and IFN-γ gene signatures were independently prognostic for patient outcomes.Conclusions
Evaluation of PD-L1 expression, TMB, and T-effector and IFN-γ gene signatures in the cohort with early-stage SqCLC found them to be independent of each other, and none was associated with overall survival. Our results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells. 相似文献3.
4.
McClelland Shearwood Degnin Catherine Chen Yiyi Watson Gordon A. Jaboin Jerry J. 《Journal of neuro-oncology》2019,141(1):159-166
Journal of Neuro-Oncology - High-volume hospitals are associated with improved outcomes in glioblastoma (GBM). However, the impact of travel burden to high-volume centers is poorly understood. We... 相似文献
5.
6.
7.
8.
9.
Mae Lynn Reyes-Rodríguez Hunna J. Watson Concepción Barrio Donald H. Baucom Yormeri Silva Kiara L. Luna-Reyes 《Eating disorders》2019,27(2):205-229
ABSTRACTLatinos are less likely to seek health care for eating disorders and more likely to drop out of treatment than members of other ethnic groups, highlighting existing challenges to engagement in traditional mental health care. This study explored the role of family in the treatment of adult Latinas with eating disorders through content analysis of family sessions adjunctive to cognitive behavioral therapy. This study yielded insight into the experiences of 10 Latinas with eating disorders (M age = 39.90 years) and 10 relatives (M age = 39.50) from the Promoviendo una Alimentación Saludable trial who were randomly selected to receive six family enhancement sessions. Data from 53 sessions were analyzed using a qualitative content analysis approach. Family intervention might serve as a valuable adjunct to conventional treatment by positively influencing social, family, and emotional support for Latinas with eating disorders. 相似文献
10.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献